Doxapram for apnoea of prematurity and neurodevelopmental outcomes at age 5-6 years.

Ludovic TréluyerElodie Zana-TaiebPierre-Henri JarreauValérie BenhammouPierre KuhnMathilde LetouzeyLaetitia Marchand-MartinWes OnlandVéronique PierratLauren SaadePierre Yves AncelHeloise Torchin

Published in: Archives of disease in childhood. Fetal and neonatal edition (2024)

In children born before 32 weeks' gestation, doxapram treatment for apnoea of prematurity was not associated with neurodevelopmental disabilities.

Keyphrases